Wuxi Apptec Co., Ltd. Class A · SSE:603259
Wuxi Apptec Co., Ltd. Class A — Investor Day (2024)
34 slides from Wuxi Apptec Co., Ltd. Class A's investor day presentation, 2024
Slide 1: WuXi Chemistry: A Global Leading CRDMO Platform
2 0 2 4 W u X i A p p Te c I n v e s t o r D a y WuXi Chemistry: A Global Leading CRDMO Platform Minzhang Chen, Ph.D. Co-CEO
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not his
Slide 3: Research Chemistry, STA and TIDES: Global Platform. Global Talent.
Research Chemistry Research Chemistry STA TIDES Small Molecule Small Molecule “R”esearch “R”esearch Small Molecule Oligonucleotides and “D”evelopment and Peptides “R”esearch, “M”anufacturing “D”evelopment and “M”anufacturing Global Platform. Global Talent. 16 22,258 2,477 sites employees clients as
Slide 4: CRDMO Business Model Drives Sustained High Growth
CRDMO Business Model Drives Sustained High Growth 4
Slide 5: 2015-2024 WuXi Chemistry Revenue
2015-2024 WuXi Chemistry Revenue (RMB ¥ 100 Million) 288.5 291.7 30.5 96.6 H2 140.9 3.5 261.2 191.9 H1 137.4 122.1 95.9 71.7 44.7 53.0 30.2 34.5 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024E non-COVID-19 Commercial Project COVID-19 Commercial Project 5
Slide 6: WuXi Chemistry H1 2024 Revenue 122.1, Increased by 2.1% vs. H1 2023
WuXi Chemistry H1 2024 Revenue 122.1, Increased by 2.1% vs. H1 2023 Excluding Major COVID-19 Product (RMB ￥100 Million) JP & KR & ROW 4.9 YoY -26.5% 15.1 4.0% CN YoY +5.8% 12.4% 19.8 16.3% 82.3 EU YoY +8.1% 67.4% NA YoY +3.0% 6
Slide 7: 454,385 compounds; H1 2024 added 644 new molecules
“R” 7%↑ 454,385 compounds 14,751 Compounds H1’ 24 added 644 new molecules 632 2,825 Preclinical & Phase 1 “D” 18%↑ 9 353 Phase II 16% of global clinical stage drugs 1 June 30, 2024 74 Phase III “M” 20%↑ 2 67 56 56 Commercial Commercial Commercial % growth of molecules in each stage June 2024 vs. Jun
Slide 8: Number of Small Molecule Phase III and Commercial Drugs
Revenue from Small Molecule Phase III Number of Small Molecule Phase III and Commercial Drugs and Commercial Drugs (Excluding COVID-19 Commercial Projects) (RMB ￥100 Million) Phase III Commercial >100% 32% 141 127 107 67 61 50 89.5 H1 66 74 46.3 57 41.5 2022 2023 H1 2024 2022 2023 2024E 8
Slide 9: Produced 21% of new drugs approved in 2024 H1
US FDA New Drug Approvals by Modality (2024H1) Oligonucleotide 4% Cell & Gene Therapy 1 11% 3 Small molecule 54% 14 8 Produced 21% of new drugs approved in 2024 H1 Biologics 31% 9
Slide 10: $30+ billion combined global sales of these drugs in 2023
$30+ billion combined global sales of these 4 drugs in 2023 Data Source: Top Small Molecule Products by Retail Sales in 2023 Complied by Evaluate Pharma 10
Slide 11: 2023 Molecules of the Year Nominees
Producing Industries Most Impactful New Therapies OUT OF 2023 Molecules of the Year Nominees “We asked our readers and reviewers to nominate molecules for our annual Molecule of the Year spot based on what you found most technically impressive and impactful. These top 10 finalists are selected based
Slide 12: WuXi Chemistry GLP-1 Pipeline Growth is Outpacing the Industry
WuXi Chemistry GLP-1 Pipeline Growth is Outpacing the Industry 不同疫苗在防护率上的差异 Clinical Stage 8 out of 47 M-RNA疫苗相比传统疫苗在预防新 型冠状病毒感染方面表现更为突出 Peptide Drugs Global clinical stage GLP-1 synthetic drug pipeline (small molecule & peptide) Clinical Stage grew from 51 to 79 (55% ↑) 10 out of 32 Small Molecule
Slide 13: WuXi Chemistry Clients
CR“DM”O C“R”DMO 1,512 539 426 “R” clients “R + DM” clients “DM” clients 2,477 WuXi Chemistry Clients +5% vs. 2023H1 13
Slide 14: WuXi Chemistry vs. Competitors Revenue 2023 1H and 2024 1H
-9.3% 13,467 12,210 2023 1H 2024 1H WuXi Chemistry Competitor 1 Competitor 2 Competitor 3 Competitor 4 Total revenue of 4 competitors in 2024 1H is 7,314￥Million RMB, 29.8% decrease vs. 2023 1H Source: companies annual reports and investor analysis report 14
Slide 15: WuXi TIDES Achieved Unprecedented Growth
WuXi TIDES Achieved Unprecedented Growth 15
Slide 16: WuXi TIDES Revenue
WuXi TIDES Revenue (RMB ¥ 100 Million) >60% H2 64% 34.1 H1 20.8 20.8 7.9 3.0 2020 2021 2022 2023 2024E 16
Slide 17: WuXi Speed
Comprehensive Capabilities Unparalleled Capacity • Vertically from research to development and • 1,000+ scientists dedicated to manufacturing oligonucleotide & peptide • Horizontally from small molecule to • 32,000+ L Solid Phase Peptide Synthesis oligonucleotide and peptide, from DS to DP, from rea
Slide 18: Solid Phase Peptide Synthesizer Reactor Volume and Peptide Produced
Solid Phase Peptide Synthesizer Peptide Product Produced Total Reactor Volume (liter) (kilogram) 41,000 35,000+ 32,000 D 17,021 6,000 4,352 4,000 2,000 74 506 711 500 2019 2020 2021 2022 2023 2024E 2019 2020 2021 2022 2023 2024E 18
Slide 19: ~20,000 children are diagnosed with DMD globally each year
Mostly affects boys and occurs in one in 3,500 to 5,000 newborns. ~20,000 children are diagnosed with DMD globally each year. Patients generally develop muscle weakness at ages of 3 and 4, gradually lose the ability to walk between 10 and 12, and die of cardiopulmonary failure between 20 and 30. Sou
Slide 20: Reduced PMO API cost by 60+%
Leading the industry with optimized processes to produce Phosphorodiamidate Morpholino Oligonucleotide (PMO) and Peptide-PMO Conjugate (PPMO) Efficiency | Capacity | Cost • Know-how to produce PMO monomers, PMO, peptide and Peptide-PMO conjugate as well as drug product — The only Accelerated timelin
Slide 21: Execution | Capacity | Speed: IND ready in 11 months
Execution | Capacity | Speed Seamless collaboration among 6 teams, integrated CMC approach enables IND ready in 11 months! Phosphorodiamidate morpholino oligomers (PMO)；Peptide-PMO (PPMO) 21
Slide 22: TIDES Molecules Using Both API and Drug Product Services
TIDES Molecules Using Both API and Drug Product Services 57 38 32 23 24 41% 31% 24% 24% 28% 10 11% 4 5% Jun-30-2021 Dec-31-2021 Jun-30-2022 Dec-31-2022 Jun-30-2023 Dec-31-2023 Jun-30-2024 Number of TIDES molecules using both API and drug produce services % TIDES molecules in our pipeline using both
Slide 23: WuXi TIDES Competitive Advantages
Peptide Drug Conjugate Radionuclide Drug Conjugate Oligonucleotide(siRNA, ASO, PMO) Peptide Conjugate Other Complex Oligonucleotide Conjugate • Comprehensive “One-stop” technology platform for WuXi TIDES oligonucleotides, peptides, ligands, linkers, lipids, etc. Competitive Advantages • Rich chemist
Slide 24: Investment in China, US, Europe and Singapore Strengthening R, D and M Network
Investment in China, US, Europe and Singapore, Further Strengthening Our “R” “D” and “M” Network 24
Slide 25: 16 Sites Across the Globe
16 Sites Across the Globe China United States Shanghai Waigaoqiao R D M Shanghai Jinshan D M San Francisco, CA R Tianjin R D Changzhou, Jiangsu D M San Diego, CA D M Wuhan, Hubei R D Changshu, Jiangsu M Middletown, DE D M Chengdu, Sichuan R Taixing #1, Jiangsu M Switzerland Singapore Qidong, Jiangsu
Slide 26: Continue to invest in meeting customer demand and strategic locations
Continue to invest in meeting customer demand and in strategic geographic locations API Taixing, China Singapore Drug Product Couvet, Switzerland Delaware, USA 26
Slide 27: All Synthetic Molecular Modalities Enabling Technology
74 ~2,000m3 11,672 All Synthetic Molecular Modalities acres total reactor volume batches delivered in 2023 • Small molecules • Oligonucleotides Enabling • HPAPI • Spray Dried Dispersion • Peptides Technology • Flow Chemistry • Preparative HPLC, SFC and SMB • Conjugates 27
Slide 28: Taixing API Site: New Plants Now Operational
Taixing API Site: 6 New Plants Now Operational Total 169 acres Phase I 9 1,000 m3 plants total reactor volume All Synthetic Molecular Modalities Small molecules │ Oligonucleotides │ Peptides │ Conjugates Customer-First Culture Quickly Responding to Demand | Maintaining Operational Excellence 2016 20
Slide 29: Taixing API Site Expansion to Meet Demand
Taixing API Site Expansion to Meet Demand Phase IIa & IIb Phase I 88-acre 81-acre 6 out of 9 plants in operation 100,000+ 3,000+ ~1,000 12,000 2024 2025 and beyond 2024 2025 and beyond 29 Small Molecule Total Reactor Volume (m3) Solid Phase Peptide Synthesizer Total Reactor Volume (L)
Slide 30: 50 acres, 7 plants: Phase 1 operating in 2027
All Synthetic Molecular Modalities Total 50 acres • Small molecules 7 plants • Oligonucleotides • Peptides Phase 1 will start operating in 2027 • Conjugates 30
Slide 31: Drug Product Current and Next Phase Expansion
Current Expansion 4 new products introduced, including 1 new commercial drug (approved by FDA & EMA) 2X oral dose capacity 2X packaging capacity (ready in Q4 2024) Next Phase Expansion • Spray dried dispersion • Parenteral formulation manufacturing Producing one of top-5 best-selling small molecule
Slide 32: Delaware Drug Product Site in US
Delaware Drug Product Site in US The new North American site to enhance Total Area: 190 acres the global supply chain through consistent service and solutions Phase I • Formulation R&D • Clinical and commercial production • Packaging, labeling, and distribution 32 Picture taken in July 2024 CONFIDEN
Slide 33: Global Quality Standard
Global Quality Standard Global Quality Inspection Highlights (2023H2 - 2024H1) 1 US FDA 1 EU EMA 7 China NMPA 1 Japan PMDA 1 SwissMedic 415 client audits 130+ 20+ successful health authority pre-approval inspections inspections since 2009 waived by US FDA and EMA 33
Slide 34: Global leading CRDMO with one stop capability
Global leading CRDMO with “one stop” capability and unparalleled capacity Unique CRDMO TIDES is bringing in business model will the next wave of continue to drive our accelerated growth strong growth 34